肺动脉高压中的种族和民族差异。
Racial and ethnic differences in pulmonary arterial hypertension.
作者信息
Al-Naamani Nadine, Paulus Jessica K, Roberts Kari E, Pauciulo Michael W, Lutz Katie, Nichols William C, Kawut Steven M
机构信息
1 14640 Pulmonary, Allergy and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
2 Institute for Clinical Research and Health Policy Studies, Department of Medicine, Tufts Medical Center, Boston, MA, USA.
出版信息
Pulm Circ. 2017 Oct-Dec;7(4):793-796. doi: 10.1177/2045893217732213. Epub 2017 Sep 15.
Abstract
This study explores the racial and ethnic differences in presentation, severity, and treatment of patients with pulmonary arterial hypertension (PAH) in a large multicenter registry. African American and Hispanic patients are more likely to present with associated PAH compared to non-Hispanic whites. Hispanic patients with PAH were less likely to be treated with PAH-specific medications compared to non-Hispanic whites.
摘要
本研究在一个大型多中心登记处中，探讨了肺动脉高压（PAH）患者在临床表现、严重程度及治疗方面的种族和民族差异。与非西班牙裔白人相比，非裔美国人和西班牙裔患者更易出现相关PAH。与非西班牙裔白人相比，患有PAH的西班牙裔患者接受PAH特异性药物治疗的可能性较小。
相似文献
1
Racial and ethnic differences in pulmonary arterial hypertension.
Pulm Circ. 2017 Oct-Dec;7(4):793-796. doi: 10.1177/2045893217732213. Epub 2017 Sep 15.
2
Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.
Ann Am Thorac Soc. 2022 Sep;19(9):1459-1468. doi: 10.1513/AnnalsATS.202109-1051OC.
3
Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension.
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1407-1415. doi: 10.1164/rccm.201907-1447OC.
4
Impact of race on survival in pulmonary arterial hypertension: Results from the REVEAL registry.
J Heart Lung Transplant. 2020 Apr;39(4):321-330. doi: 10.1016/j.healun.2019.11.024. Epub 2020 Jan 24.
5
Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA).
Am J Hypertens. 2004 Oct;17(10):963-70. doi: 10.1016/j.amjhyper.2004.06.001.
6
Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study.
Ann Pharmacother. 2009 Feb;43(2):185-93. doi: 10.1345/aph.1L368. Epub 2009 Feb 3.
7
Differences in the expression of DNA methyltransferases and demethylases in leukocytes and the severity of pulmonary arterial hypertension between ethnic groups.
Physiol Rep. 2022 May;10(10):e15282. doi: 10.14814/phy2.15282.
8
Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry.
J Pediatr. 2019 Aug;211:63-71.e6. doi: 10.1016/j.jpeds.2019.04.046. Epub 2019 Jun 5.
9
Racial/Ethnic Differences in Psychiatric and Medical Diagnoses Among Autistic Adults.
Autism Adulthood. 2022 Dec 1;4(4):290-305. doi: 10.1089/aut.2021.0083. Epub 2022 Dec 13.
10
Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association.
Stroke. 2011 Jul;42(7):2091-116. doi: 10.1161/STR.0b013e3182213e24. Epub 2011 May 26.
引用本文的文献
1
Important Differences in Disease Severity, Echocardiography Findings, and Referral Delays in Non-Hispanic Black Patients With Pulmonary Arterial Hypertension.
Pulm Circ. 2025 Jul 28;15(3):e70138. doi: 10.1002/pul2.70138. eCollection 2025 Jul.
2
Clinical characteristics, treatment patterns and healthcare resource utilisation for portopulmonary hypertension patients in the USA: a real-world study.
BMJ Open. 2025 Jun 19;15(6):e089223. doi: 10.1136/bmjopen-2024-089223.
3
Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact for Clinical Use (SYMPACT-CP): a qualitative interview study.
BMC Pulm Med. 2025 May 6;25(1):217. doi: 10.1186/s12890-025-03681-2.
4
Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.
Int J Cardiol Congenit Heart Dis. 2025 Jan 31;19:100573. doi: 10.1016/j.ijcchd.2025.100573. eCollection 2025 Mar.
5
Demographic, hemodynamic characteristics, and therapeutic trends of pulmonary hypertension patients: The Pulmonary Hypertension Mexican registry (REMEHIP).
Pulm Circ. 2024 Jun 17;14(2):e12395. doi: 10.1002/pul2.12395. eCollection 2024 Apr.
6
Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.
Cardiol Ther. 2024 Jun;13(2):315-339. doi: 10.1007/s40119-024-00361-w. Epub 2024 Mar 7.
7
Pulmonary Hypertension in Underrepresented Minorities: A Narrative Review.
J Clin Med. 2024 Jan 4;13(1):285. doi: 10.3390/jcm13010285.
8
Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience.
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231199693. doi: 10.1177/17534666231199693.
9
Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension.
Pulm Circ. 2023 Aug 7;13(3):e12271. doi: 10.1002/pul2.12271. eCollection 2023 Jul.
10
is a candidate gene in sickle cell disease-associated pulmonary hypertension and pulmonary arterial hypertension.
Pulm Circ. 2023 Apr 1;13(2):e12227. doi: 10.1002/pul2.12227. eCollection 2023 Apr.
本文引用的文献
1
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.
2
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.
3
Gender and racial differences in nonalcoholic fatty liver disease.
World J Hepatol. 2014 May 27;6(5):274-83. doi: 10.4254/wjh.v6.i5.274.
4
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.
5
Riociguat for the treatment of pulmonary arterial hypertension.
N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655.
6
Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.
Medicine (Baltimore). 2013 Jul;92(4):191-205. doi: 10.1097/MD.0b013e31829be125.
7
Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004.
Arthritis Rheum. 2013 Mar;65(3):753-63. doi: 10.1002/art.37795.
8
Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
Chest. 2012 Jan;141(1):20-26. doi: 10.1378/chest.11-0404. Epub 2011 Sep 22.
9
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.
Chest. 2010 Feb;137(2):376-87. doi: 10.1378/chest.09-1140. Epub 2009 Oct 16.
10
Increased mortality in African Americans with idiopathic pulmonary arterial hypertension.
J Natl Med Assoc. 2008 Jan;100(1):69-72. doi: 10.1016/s0027-9684(15)31177-9.
Zotero 插件